Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 31 2025
0mins
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FOLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FOLD
Wall Street analysts forecast FOLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 14.25 USD with a low forecast of 11.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 14.270
Low
11.00
Averages
14.25
High
19.00
Current: 14.270
Low
11.00
Averages
14.25
High
19.00
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
Continue Reading
BioMarin Expects Strong Sales for Voxzogo in Q4
- Voxzogo Sales Outlook: BioMarin anticipates that its rare disease drug Voxzogo will achieve its highest sales level in Q4 2024, as CFO Brian Mueller indicated during the Q3 earnings call, which is expected to drive revenue growth and bolster investor confidence.
- Guidance Adjustment: The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting optimistic expectations for Q4 performance, which may reduce the risk of negative surprises in earnings reports and further solidify market trust in the company.
- FDA Approval Catalyst: BioMarin expects to receive an FDA approval decision for Palynziq on February 28, 2026, which could provide new growth opportunities for the company, with potential EU approval also anticipated in the first half of the year.
- Competition Risks: Despite BioMarin's optimistic outlook for Voxzogo, management acknowledged potential competitive pressures that could impact market share in 2027, necessitating careful risk assessment by investors.
Continue Reading